LAE005 + afuresertib + nab-paclitaxel

This is an experimental **three-drug combination therapy** consisting of **LAE005**, **afuresertib**, and **nab-paclitaxel**. - **LAE005**: Little publicly available information; presumed to be an investigational compound from Laekna, possibly with antineoplastic properties, mechanism not publicly disclosed as of September 2025. - **Afuresertib**: A small molecule, orally administered, ATP-competitive, pan-AKT kinase inhibitor developed as an antineoplastic agent. It inhibits AKT1, AKT2, and AKT3, disrupting the PI3K/AKT signaling pathway, which is important in cancer cell survival, proliferation, and drug resistance[1][3][4]. - **Nab-paclitaxel**: Nanoparticle albumin-bound form of the antineoplastic agent paclitaxel; functions by stabilizing microtubules and inhibiting cell division, used in various solid malignancies. This combination is under clinical investigation for **advanced or resistant cancers**, particularly those with aberrant PI3K/AKT signaling or where AKT inhibition improves response to taxane chemotherapy.

Other names

albumin-bound paclitaxel